Company Overview of OncoMed Pharmaceuticals, Inc.
OncoMed Pharmaceuticals, Inc., a clinical development-stage biotechnology company, discovers and develops protein therapeutics targeting cancer stem cells (CSCs). Its product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, as well as impact bulk tumor cells. The company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), a humanized monoclonal antibody that is in two Phase II clinical trials and one Phase Ib/II clinical trial for the treatment of patients with non-small-cell lung cancer and pancreatic cancer; Anti-DLL4/Anti-vascular endothelial growth factor (VEGF) Bispecific, which has c...
800 Chesapeake Drive
Redwood City, CA 94063
Founded in 2004
Key Executives for OncoMed Pharmaceuticals, Inc.
Chairman, Chief Executive Officer and President
Total Annual Compensation: $469.5K
Vice President and General Counsel
Total Annual Compensation: $383.8K
Chief Medical Officer and Senior Vice President
Total Annual Compensation: $377.2K
Chief Scientific Officer and Executive Vice President
Total Annual Compensation: $364.7K
Compensation as of Fiscal Year 2014.
OncoMed Pharmaceuticals, Inc. Key Developments
OncoMed Pharmaceuticals, Inc. Presents Updated Demcizumab Data in Non-Small Cell Lung Cancer at the 2015 ASCO Annual Meeting
Jun 1 15
At the 2015 ASCO Annual Meeting, OncoMed Pharmaceuticals Inc. presented data from a Phase 1b study open-label trial of demcizumab plus carboplatin and pemetrexed (Alimta) in patients with first-line advanced stage non-small cell lung cancer (NSCLC). Demcizumab is a first-in-class monoclonal antibody targeting DLL4 with anti-cancer stem cell, dysangiogenic and potential immune modulatory properties. Patients enrolled in the multi-center Phase 1b study either received six cycles of pemetrexed and carboplatin with demcizumab administered every three weeks on a continuous dosing schedule or four cycles of pemetrexed and carboplatin with truncated dosing of demcizumab followed by pemetrexed maintenance. Kaplan-Meier curves for the continuous dose cohort reveal prolonged progression-free survival and overall survival in a subset of demcizumab-treated patients. Of 23 patients in the continuous dosing cohort, ten (approximately 40%) survived more than two years. In these ten patients who survived more than 300 days, represented in the tail on the Kaplan-Meier survival curve, there was a cumulative 21.8 years of patient follow-up beyond those 300 days, and among these ten patients, only two patient deaths occurred as of the February 26, 2015 data cut off. Survival data from patients treated with the truncated demcizumab dose regimen is less mature, although the Kaplan-Meier curve shows a similar trajectory as of the February 2015 cut-off date. A retrospective analysis of patient tumor samples was conducted looking at a number of biomarkers related to demcizumab's mechanism of action, including tumor expression of the DLL4 protein, tumor expression of the programmed death receptor ligand-1 (PD-L1), and presence of immune cells within tumors, in order to identify potential predictive biomarkers for the apparent prolonged survival of certain patients treated with demcizumab. A total of 46 patients were enrolled in the Phase 1b study, with 40 evaluable for efficacy across both cohorts. One patient (3%) had a complete response, 19 (48%) had partial responses and 15 (38%) had stable disease as measured by RECIST criteria. The overall clinical benefit rate was 88%.
OncoMed Pharmaceuticals, Inc. - Special Call
May 28 15
To discuss clinical-stage company developing novel therapeutics that target cancer stem cell
OncoMed Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 08:00 AM
May 28 15
OncoMed Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 08:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Paul J. Hastings, Chairman, Chief Executive Officer and President.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|